StoxGlobal Health vs Dr. Lal Path Labs: share price & financials comparison
NSE: MEDANTA vs LALPATHLAB · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Global Health vs Dr. Lal Path Labs at a glance
Global Health (MEDANTA) has a market capitalisation of ₹39,065 Cr, against ₹33,443 Cr for Dr. Lal Path Labs (LALPATHLAB). Over the past year Dr. Lal Path Labs has returned +26.4%, compared with +16.4% for Global Health. On valuation, Dr. Lal Path Labs trades at a lower P/E of 57.3 versus 98.2. Dr. Lal Path Labs earns a higher return on equity (21.3% vs 9.2%). Global Health comes out ahead on size and growth. Dr. Lal Path Labs comes out ahead on valuation, profitability and technicals. Across the scored metrics below, Global Health leads on 6 and Dr. Lal Path Labs on 9. On StoxGud's 10-point checklist, Global Health scores 6/10 and Dr. Lal Path Labs scores 9/10.
| Metric | Global Health | Dr. Lal Path Labs |
|---|---|---|
| Size | ||
| Market cap | ₹39,065 Cr | ₹33,443 Cr |
| Revenue (latest FY) | ₹4,410 Cr | ₹2,763 Cr |
| Net profit (latest FY) | ₹556 Cr | ₹505 Cr |
| Valuation | ||
| P/E | 98.2 | 57.3 |
| P/B | 9.04 | 12.19 |
| Dividend yield | 0.03% | 0.67% |
| Profitability | ||
| Return on equity | 9.2% | 21.3% |
| Net profit margin | 7.9% | 19.2% |
| Operating margin | 22.1% | 29.5% |
| Growth | ||
| Revenue growth (YoY) | +33.6% | +19.6% |
| Net profit growth (YoY) | -100.0% | +27.6% |
| Revenue CAGR (multi-year) | +17.9% | +11.8% |
| Financial health | ||
| Debt to equity | 0.16 | 0.00 |
| Momentum | ||
| 1-month return | +13.6% | +4.3% |
| 1-year return | +16.4% | +26.4% |
| 3-year CAGR | +16.9% | +15.0% |
| 5-year CAGR | — | +1.7% |
| 10-year CAGR | — | +13.7% |
| Distance from 52W high | -3.6% | -1.8% |
| Technicals | ||
| RSI (14) | 88 | 68 |
| Price vs 200-day avg | +15.9% | +19.8% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Global Health | Dr. Lal Path Labs |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✓ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✗ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✗ | ✓ |
| P/E below industry median | ✗ | ✗ |
| Score | 6/10 | 9/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Global Health or Dr. Lal Path Labs?
Global Health has a market cap of ₹39,065 Cr and Dr. Lal Path Labs has a market cap of ₹33,443 Cr as of 13 Nov 2026.
Which has a lower P/E, Global Health or Dr. Lal Path Labs?
Dr. Lal Path Labs has the lower P/E: Global Health trades at 98.2 and Dr. Lal Path Labs at 57.3.
Which gave better returns in the last year, Global Health or Dr. Lal Path Labs?
Dr. Lal Path Labs did better: Global Health returned +16.4% and Dr. Lal Path Labs returned +26.4% over one year.
What is the difference between Global Health and Dr. Lal Path Labs?
Both are NSE-listed companies in Healthcare. Global Health is about 1.2 times the size of Dr. Lal Path Labs by market cap. In the latest financial year Global Health reported revenue of ₹4,410 Cr and Dr. Lal Path Labs ₹2,763 Cr. Operating margin is 22.1% for Global Health and 29.5% for Dr. Lal Path Labs. Debt to equity is 0.16 for Global Health and 0.00 for Dr. Lal Path Labs.
Which is better, Global Health or Dr. Lal Path Labs?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Global Health leads on 6 and Dr. Lal Path Labs on 9. Global Health is ahead on size and growth. Dr. Lal Path Labs is ahead on valuation, profitability and technicals. On StoxGud's rules-based checklist Global Health scores 6/10 and Dr. Lal Path Labs scores 9/10. This is information, not advice: consult a SEBI-registered adviser before investing.